Dr. Pautler graduated with high honors from the University of Florida where he was inducted into Phi Eta Sigma honor society. He obtained his retina training at the prestigious Bascom Palmer Eye Institute at the University of Miami. He continues to participate in clinical research and is a Clinical Associate Professor at the University of South Florida. He has been named 3 times in the listing of Best Doctors of America. MORE
Steven Cohen, MD
Dr. Cohen graduated with honors from Harvard College in Mathematics and completed his medical training at Harvard Medical School. He completed two years of Retina fellowship training at the Bascom Palmer Eye Institute at the University of Miami. He is a Clinical Professor of Ophthalmology at the University of South Florida and a Fellow of the American Academy of Ophthalmology. MORE
Karina Billiris-Findlay, MD
Dr. Billiris Findlay has been practicing retina since 1997. She graduated Summa Cum Laude from the University of South Florida in Chemistry. She completed her medical training and Ophthalmology Residency at USF and her Retina Fellowship with Retina-Vitreous Associates of Florida. She is a member of the Alpha Omega Alpha medical honor society, a Fellow of the American College of Surgeons and a Clinical Assistant Professor of Ophthalmology. MORE
David Eichenbaum, MD
Dr. Eichenbaum is a board certified ophthalmologist specializing in diseases and surgery of the vitreous and retina. He earned his medical degree at the University of South Florida in Tampa and completed his ophthalmology residency at the University of South Florida. Dr. Eichenbaum completed his two year vitreo-retinal fellowship at Tufts University in Boston. He has published in several professional journals and textbook chapters. MORE
In a move to diversify its business and gain ground in
the rapidly growing global eye-care business, Novartis AG
(Basel, Switzerland) announced in January a deal to purchase
a majority stake in Alcon, Inc. (Huenenberg,
Switzerland).
Novartis said it would pay $28.1 billion for a majority
stake in Alcon, with plans to acquire the rest of the s...
Oraya Therapeutics, Inc. (Newark, CA), began enrollment
for what the company called the first sham-controlled
study to demonstrate the efficacy and safety of
radiation therapy for the treatment of wet age-related
macular degeneration (AMD).According to a company news release, the trial will be
conducted at seven sites in Europe and will includ...
Investigators for the Fluocinolone Acetonide in Diabetic
Macular Edema (FAME) trial reported positive results
from two phase 3 trials of Iluvien (Alimera Sciences, Inc.,
Alpharetta, GA), an extended release, nonerodable
injectable fluocinolone intravitreal implant. According to
the company, each Iluvien insert delivers sustained submicrogram
...
